211 related articles for article (PubMed ID: 12668605)
1. Intermediate filament aggregation in fibroblasts of giant axonal neuropathy patients is aggravated in non dividing cells and by microtubule destabilization.
Bomont P; Koenig M
Hum Mol Genet; 2003 Apr; 12(8):813-22. PubMed ID: 12668605
[TBL] [Abstract][Full Text] [Related]
2. Gigaxonin is required for intermediate filament transport.
Renganathan B; Zewe JP; Cheng Y; Paumier JM; Kittisopikul M; Ridge KM; Opal P; Gelfand VI
FASEB J; 2023 May; 37(5):e22886. PubMed ID: 37043392
[TBL] [Abstract][Full Text] [Related]
3. Abnormal intermediate filament organization alters mitochondrial motility in giant axonal neuropathy fibroblasts.
Lowery J; Jain N; Kuczmarski ER; Mahammad S; Goldman A; Gelfand VI; Opal P; Goldman RD
Mol Biol Cell; 2016 Feb; 27(4):608-16. PubMed ID: 26700320
[TBL] [Abstract][Full Text] [Related]
4. Microtubule-associated protein 1B: a neuronal binding partner for gigaxonin.
Ding J; Liu JJ; Kowal AS; Nardine T; Bhattacharya P; Lee A; Yang Y
J Cell Biol; 2002 Aug; 158(3):427-33. PubMed ID: 12147674
[TBL] [Abstract][Full Text] [Related]
5. The gene encoding gigaxonin, a new member of the cytoskeletal BTB/kelch repeat family, is mutated in giant axonal neuropathy.
Bomont P; Cavalier L; Blondeau F; Ben Hamida C; Belal S; Tazir M; Demir E; Topaloglu H; Korinthenberg R; Tüysüz B; Landrieu P; Hentati F; Koenig M
Nat Genet; 2000 Nov; 26(3):370-4. PubMed ID: 11062483
[TBL] [Abstract][Full Text] [Related]
6. Gigaxonin controls vimentin organization through a tubulin chaperone-independent pathway.
Cleveland DW; Yamanaka K; Bomont P
Hum Mol Genet; 2009 Apr; 18(8):1384-94. PubMed ID: 19168853
[TBL] [Abstract][Full Text] [Related]
7. Aggregation of a subpopulation of vimentin filaments in cultured human skin fibroblasts derived from patients with giant axonal neuropathy.
Bousquet O; Basseville M; Vila-Porcile E; Billette de Villemeur T; Hauw JJ; Landrieu P; Portier MM
Cell Motil Cytoskeleton; 1996; 33(2):115-29. PubMed ID: 8635201
[TBL] [Abstract][Full Text] [Related]
8. Giant axonal neuropathy-associated gigaxonin mutations impair intermediate filament protein degradation.
Mahammad S; Murthy SN; Didonna A; Grin B; Israeli E; Perrot R; Bomont P; Julien JP; Kuczmarski E; Opal P; Goldman RD
J Clin Invest; 2013 May; 123(5):1964-75. PubMed ID: 23585478
[TBL] [Abstract][Full Text] [Related]
9. Restoration of cytoskeleton homeostasis after gigaxonin gene transfer for giant axonal neuropathy.
Mussche S; Devreese B; Nagabhushan Kalburgi S; Bachaboina L; Fox JC; Shih HJ; Van Coster R; Samulski RJ; Gray SJ
Hum Gene Ther; 2013 Feb; 24(2):209-19. PubMed ID: 23316953
[TBL] [Abstract][Full Text] [Related]
10. Calpain-mediated proteolysis of vimentin filaments is augmented in giant axonal neuropathy fibroblasts exposed to hypotonic stress.
Phillips CL; Fu D; Herring LE; Armao D; Snider NT
Front Cell Dev Biol; 2022; 10():1008542. PubMed ID: 36393840
[TBL] [Abstract][Full Text] [Related]
11. Intermediate filament protein accumulation in motor neurons derived from giant axonal neuropathy iPSCs rescued by restoration of gigaxonin.
Johnson-Kerner BL; Ahmad FS; Diaz AG; Greene JP; Gray SJ; Samulski RJ; Chung WK; Van Coster R; Maertens P; Noggle SA; Henderson CE; Wichterle H
Hum Mol Genet; 2015 Mar; 24(5):1420-31. PubMed ID: 25398950
[TBL] [Abstract][Full Text] [Related]
12. Explaining intermediate filament accumulation in giant axonal neuropathy.
Opal P; Goldman RD
Rare Dis; 2013; 1():e25378. PubMed ID: 25003002
[TBL] [Abstract][Full Text] [Related]
13. The instability of the BTB-KELCH protein Gigaxonin causes Giant Axonal Neuropathy and constitutes a new penetrant and specific diagnostic test.
Boizot A; Talmat-Amar Y; Morrogh D; Kuntz NL; Halbert C; Chabrol B; Houlden H; Stojkovic T; Schulman BA; Rautenstrauss B; Bomont P
Acta Neuropathol Commun; 2014 Apr; 2():47. PubMed ID: 24758703
[TBL] [Abstract][Full Text] [Related]
14. Immunocytochemical studies of intermediate filament aggregates and their relationship to microtubules in cultured skin fibroblasts from patients with giant axonal neuropathy.
Pena SD; Opas M; Turksen K; Kalnins VI; Carpenter S
Eur J Cell Biol; 1983 Sep; 31(2):227-34. PubMed ID: 6315439
[TBL] [Abstract][Full Text] [Related]
15. A review of gigaxonin mutations in giant axonal neuropathy (GAN) and cancer.
Kang JJ; Liu IY; Wang MB; Srivatsan ES
Hum Genet; 2016 Jul; 135(7):675-84. PubMed ID: 27023907
[TBL] [Abstract][Full Text] [Related]
16. Gigaxonin-controlled degradation of MAP1B light chain is critical to neuronal survival.
Allen E; Ding J; Wang W; Pramanik S; Chou J; Yau V; Yang Y
Nature; 2005 Nov; 438(7065):224-8. PubMed ID: 16227972
[TBL] [Abstract][Full Text] [Related]
17. Kelch Domain of Gigaxonin Interacts with Intermediate Filament Proteins Affected in Giant Axonal Neuropathy.
Johnson-Kerner BL; Garcia Diaz A; Ekins S; Wichterle H
PLoS One; 2015; 10(10):e0140157. PubMed ID: 26460568
[TBL] [Abstract][Full Text] [Related]
18. A New Mouse Model of Giant Axonal Neuropathy with Overt Phenotypes and Neurodegeneration Driven by Neurofilament Disorganization.
Nath B; Julien JP
J Neurosci; 2023 May; 43(22):4174-4189. PubMed ID: 37137704
[TBL] [Abstract][Full Text] [Related]
19. Evidence that formation of an intermediate filament-protein complex plays a primary role in aggregation of neurofilaments, glial fibrillary acidic protein (GFAP)-filaments and vimentin-filaments by 2,5-hexanedione.
Durham HD; Salera I; Dahrouge S
J Neuropathol Exp Neurol; 1989 Mar; 48(2):197-211. PubMed ID: 2466109
[TBL] [Abstract][Full Text] [Related]
20. Alterations in lipid metabolism gene expression and abnormal lipid accumulation in fibroblast explants from giant axonal neuropathy patients.
Leung CL; Pang Y; Shu C; Goryunov D; Liem RK
BMC Genet; 2007 Mar; 8():6. PubMed ID: 17331252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
